Meridian Bioscience Rises On Unusually High Volume (VIVO)

NEW YORK ( TheStreet) -- Meridian Bioscience (Nasdaq: VIVO) is trading at unusually high volume Wednesday with 1.5 million shares changing hands. It is currently at 6.7 times its average daily volume and trading up 35 cents (+2%) at $17.79 as of 3:15 p.m. ET.

Meridian Bioscience has a market cap of $817 million and is part of the health care sector and drugs industry. Shares are down 7.4% year to date as of the close of trading on Tuesday.

Meridian Bioscience, Inc., a life science company, engages in the development, manufacture, sale, and distribution of diagnostic test kits primarily for gastrointestinal, foodborne, viral, respiratory, and parasitic infectious diseases. The company's diagnostic products primarily consist of C. The company has a P/E ratio of 24.7, below the average drugs industry P/E ratio of 30.5 and above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Meridian Bioscience as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity and growth in earnings per share. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself and premium valuation. You can view the full Meridian Bioscience Ratings Report.

See all heavy volume stocks in our stocks moving on unusual volume list or get investment ideas from our investment research center.

Interested in other stocks that are rising on unusually high volume? Get free SMS text alerts sent to you when the action happens by texting HVUP to 95370 or select from multiple alert options.